Business Standard
Thursday, May 31, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||||||Life & Leisure||| 
 Section Home | People | Features | Enterprise | Columnists | Gadgets & Gizmos | Travel | How to Spend It | Book Review | Leisure & Sports
Home > Life & Leisure
 

Red flag for the runs
Anand Sankar / New Delhi Jun 07, 2009, 00:23 IST

After drug controllers in numerous countries, the WHO has also given its approval to the diarrhoea vaccine

This should come as good news for parents who have to deal with infants and children suffering from the runs. The World Health Organisation (WHO) has given its nod to a vaccine that builds immunity against the diarrhoea-causing rotavirus. Though the vaccine has been available via retail in many Western countries and even in India, this announcement is significant because aid programmes around the world which undertake immunisation of children can now include this vaccine.

The rotavirus is a relatively recent discovery. It was isolated in 1973, and soon the WHO found that it was responsible for more than 500,000 diarrhoeal deaths and two million hospitalisations a year among children. Thus, the agency justifies its approval for a vaccine to combat the virus. It is said that by the age of five nearly every child in the world has been infected with the rotavirus at least once. But with each infection immunity develops, and subsequent infections are less severe. Adults are said to rarely be affected.

A vaccine for the rotavirus was ready for clinical trials in 1998. Trials in the USA, Finland and Venezuela found it to be 80-100 per cent effective at preventing severe diarrhoea and, even better, researchers detected no “statistically significant serious adverse effects”. The WHO's Strategic Advisory Group of Experts (SAGE) made its recommendations in the wake of new data from fresh clinical trials done in 2006.

The vaccine is available from two pharma majors — GlaxoSmithKline and Merck. The former calls it Rotarix and the latter RotaTeq. Both are taken orally and contain disabled live virus. Both companies are expected to reap the benefits of the WHO nod. But there is already controversy, because the UK agency that recommends vaccines to the UK’s National Health Service has said the vaccines are “too costly”, and the US Joint Committee on Vaccination and Immunisation has said it would only consider recommending the vaccine if its price was significantly reduced. Aid agencies, though, say that, notwithstanding the cost, the vaccine is a boon for areas like Africa.

But the WHO has said in a footnote that other causative factors for diarrhoea remain. It is also important to improve water quality, hygiene and sanitation, and to ensure that oral rehydration solutions and zinc supplements are available.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets end lower ahead of May F&O expiry
- Parsvnath posts Rs 23 cr loss in Q4
- Educomp net down 57% at Rs 61 cr in Jan-Mar qtr
- DLF Q4 net plunges 39% to Rs 211 cr
- Provogue Q4 net profit down 71% at Rs 1.81 cr
  Read Business news in 
- India's no. 1 Property Site. Click here to know more
- "Discover The Power of One"
- Help a Child Achieve her. Click to know more
- The Best Seller is Also the No. 1 in Mileage. Click here
- Watch The Film Here. Click here to know more..
- Learn How One City is Running on FOOD SCRAPS.
- 1 billion in saving for Unilever without any tangles.
- One Partnership Endless Possibilities. Click here to know more
- Helping doctors detect diseases earlier, saving costs & extending lives.
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
- 2 Lac Apartments, 1 Lac House / Plots. Click here
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- Vodafone notice on arbitration premature: Govt
- Coal blocks for infrastructure projects get GoM nod
- Tata Motors skids as margins dip at JLR
- Toyota looks at more small cars for India
- Rupee-sensitive stocks risky for new investors
 
 More  
New Ipad Application
 Business Standard's all new IPad  App
 Click here to download for free
  Hot Searches  
 
Apalya |  Air India |  GAAR |  Agni  |  Solar eclipse |  Satyamev Jayate |  SRK |  Aamir Khan |  IPL |  Ertiga |  Sarfaesi Act |  Vodafone |  JP Morgan |  Transfer pricing |  Rupee |  Kingfisher Airlines |  Silver |  Provident Fund |  income tax refund |  iPhone |  Reliance Industries |  SEBI |  BSNL |  BSE |  NSE |  Mukesh Ambani |  Anil Ambani |  Infosys |  Pranab Mukherjee |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us